83 - Predictors of Undetectable HDV RNA 48 weeks after completion of finite treatment with Bulevirtide and Pegylated-Interferon Alpha 2a

Thursday, October 17, 2024

10:45 AM – 11:00 AM US PT

Location: 404 AB

Presenting Author(s)

Pavel Bogomolov, MD, Ph.D (he/him/his)

Head of hepatology dept.
M.F. Vladimirsky Moscow Regional Research and Clinical Institute, Moscow, Russian Federation
Moscow, Moskva, Russia

Slides

Co-Author(s)

TS

Tatyana Stepanova, MD

LLC Clinic of Modern Medicine, Moscow, Russian Federation
Moscow, Moskva, Russia
VM

Viacheslav Morozov, MD, PhD

LLC Medical Company Hepatolog, Samara, Russian Federation
Samara, Samara, Russia
TA

Tarik Asselah, PhD

Hopital Beaujob APHP, Universite de Paris, INSERM
Clichy, Ile-de-France, France
FZ

Fabien Zoulim, MD, PhD

Hospital Croix Rousse
Lyon, Rhone-Alpes, France
AS

Adrian Streinu-Cercel, PhD

Matei Bals National Institute of Infectious Diseases, Bucharest, Romania; "Carol Davila" University of Medicine and Pharmacy
Bucharest, Bucuresti, Romania
GG

George Sebastian Gherlan, MD, PhD

"Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania; Dr. Victor Babes Foundation
Bucharest, Bucuresti, Romania
OS

Olga Sagalova, MD, PhD

South Ural State Medical University, Chelyabinsk, Russian Federation
Chelyabinsk, Moskva, Russia
DT

Dana Tedesco, PhD

Gilead Sciences, Inc.
Foster City, California, United States
RM

Renee-Claude Mercier, PharmD

Gilead Sciences, Inc.
Foster City, California, United States
LY

Lei Ye, PhD

Gilead Sciences, Inc.
Foster City, California, United States
Dmitry Manuilov, MD

Sr. Director, Virology Clinical Development
Gilead Sciences, Inc.
Foster City, California, United States
AL

Audrey Lau, MD, PhD

Gilead Sciences, Inc.
Foster City, California, United States
MB

Marc Bourliere, MD, PhD

Hopital Saint Joseph
Marseille, Provence-Alpes-Cote d'Azur, France
VC

Vladimir Chulanov, MD, PhD

Sechenov University
Moscow, Moskva, Russia

Disclosure(s):

Pavel Bogomolov, MD, Ph.D: No financial relationships to disclose

Tarik Asselah, PhD: Abbvie: Expert Testimony, Investigator; Eiger Pharmaceuticals: Expert Testimony, Investigator; Gilead Sciences, Inc.: Expert Testimony, Investigator; Janssen: Expert Testimony, Investigator; Merck: Expert Testimony, Investigator; Myr pharmaceutical: Expert Testimony, Investigator; Roche: Expert Testimony, Investigator

Fabien Zoulim, MD, PhD: Aligos Therapeutics: consulting fees; Antios Therapeutics: consulting fees; Assembly Biosciences: consulting fees, Grant/Research Support; Beam Therapeutics: Grant/Research Support; Gilead Sciences, Inc.: consulting fees; Janssen: Grant/Research Support

Adrian Streinu-Cercel, PhD: No financial relationships to disclose

George Sebastian Gherlan, MD, PhD: No financial relationships to disclose

Dana Tedesco, PhD: Gilead Sciences, Inc.: Employee, Stocks/Bonds (Private Company)

Renee-Claude Mercier, PharmD: Gilead Sciences, Inc.: Employee, Stocks/Bonds (Private Company)

Dmitry Manuilov, MD: Gilead Sciences, Inc.: Employee, Stocks/Bonds (Private Company)

Audrey Lau, MD, PhD: Gilead Sciences, Inc.: Employee, Stocks/Bonds (Private Company)

Marc Bourliere, MD, PhD: AbbVie: Board Member, Expert Testimony; Gilead Sciences, Inc.: Board Member, Expert Testimony; Intercept: Board Member, Expert Testimony; Roche: Board Member, Expert Testimony

Vladimir Chulanov, MD, PhD: AbbVie: Advisor/Consultant, Expert Testimony; AstraZeneca: Advisor/Consultant, Expert Testimony; Bristol Myers Squibb: Advisor/Consultant, Expert Testimony; Gilead Sciences, Inc.: Advisor/Consultant, Expert Testimony; GSK: Advisor/Consultant, Expert Testimony; Hepatera: Advisor/Consultant, Expert Testimony; Merck Sharp & Dohme: Advisor/Consultant, Expert Testimony; Roche: Advisor/Consultant, Expert Testimony; R-Pharm: Advisor/Consultant, Expert Testimony